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ABSTRACT
IRF1 (Interferon Regulatory Factor-1) is the prototype
of the IRF family of DNA binding transcription factors.
IRF1 protein expression is regulated by transient up-
regulation in response to external stimuli followed by
rapid degradation via the ubiquitin-proteasome sys-
tem. Here we report that DNA bound IRF1 turnover
is promoted by GSK3 (Glycogen Synthase Kinase
3) via phosphorylation of the T181 residue which
generates a phosphodegron for the SCF (Skp-Cul-
Fbox) ubiquitin E3-ligase receptor protein Fbxw7
(F-box/WD40 7). This regulated turnover is essen-
tial for IRF1 activity, as mutation of T181 results in
an improperly stabilized protein that accumulates at
target promoters but fails to induce RNA-Pol-II elon-
gation and subsequent transcription of target genes.
Consequently, the anti-proliferative activity of IRF1 is
lost in cell lines expressing T181A mutant. Further,
cell lines with dysfunctional Fbxw7 are less sensi-
tive to IRF1 overexpression, suggesting an impor-
tant co-activator function for this ligase complex.
As T181 phosphorylation requires both DNA bind-
ing and RNA-Pol-II elongation, we propose that this
event acts to clear ‘spent’ molecules of IRF1 from
transcriptionally engaged target promoters.
INTRODUCTION
IRF1 is a transcription factor essential for regulating a
number of cellular responses including, immunity, apopto-
sis and DNA repair (1–5). IRF1 is highly modified by sev-
eral post-translational modifications. Phosphorylation of a
cluster of residues in the C terminus by casein kinase II
may be required for activity as mutation of these residues
reduces reporter activity (6). These residues overlap with
sites reported to be targeted by IKKε, and may be involved
in interactions with RelA (7). IRF1 is also phosphorylated
on Y109 in the DBD (DNA binding domain). This mod-
ification plays a role in dimerization with IRF8 and tran-
scriptional activity (8). IRF1 also undergoes a number of
other modifications, including SUMOylation (9) methyla-
tion (10) and acetylation (11). Mechanistically our under-
standing of how these modifications regulate IRF1 activity
is still poorly understood.
IRF1 is a highly unstable protein with a half-life of
around 30 minutes (12) that can be stabilized through inter-
action with the chaperone Hsp90 (13). Several studies have
investigated the ubiquitin (Ub) dependent regulation of
IRF1 turnover (14–16), highlighting roles for both MDM2
and CHIP (C-terminus of HSC70 interacting protein) E3
ligases in ubiquitination of IRF1 protein. In these studies,
IRF1 ismodified byUbpolymers formed through bothK48
andK63 linkages (14–18).While a role for ubiquitination in
the proteasome-mediated degradation of IRF1 is clear, lit-
tle is known regarding what signals ubiquitination of IRF1
and if turnover regulates IRF1 transcriptional activity be-
yond regulating abundance.
Crosstalk between phosphorylation and the Ub machin-
ery is important for regulating protein quantity, activity
and interactions (19,20). In some contexts phosphorylation
generates PTM motifs (phospho-degrons) that are recog-
nized by receptor proteins associated with the ubiquitin-
proteasome degradation machinery. The activities of mul-
tiple transcription factors are regulated by this type of
cross-talk (20). Consequently phosphorylation can serve
as an important regulatory switch in target ubiquitina-
tion and degradation. GSK3 is a serine/threonine ki-
nase with a preference for a +4 ‘priming’ phosphorylated
or acidic residue for effective catalysis. Many transcrip-
tion factors targeted for phosphorylation-mediated degra-
dation areGSK3 substrates, in concert withFbxw7, a SCF
(Skp-Cul-Fbox) phospho-substrate receptor protein (21–
25). GSK3 is known to play a role in cancer and has been
documented as having both cancer promoting and cancer
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inhibiting functions. Together with GSK3, Fbxw7 con-
trols the turnover of a number of key oncogenes such as
c-Myc, Cyclin E and NOTCH (26–30) and has emerged as
an important tumour suppressor that is frequently mutated
in cancer (31).
While IRF1 is known to be extensively modified, rela-
tively little is known about how IRF1 activity is modu-
lated at the posttranslational level. In this study we focused
on a pair of previously uncharacterized phosphorylation
sites and uncovered a novel mechanism by which cells mark
IRF1 as ‘spent’ at the end of the transcriptional cycle.
MATERIALS AND METHODS
Cell lines, siRNA, antibodies and chemicals
Cells were maintained in the recommended growth me-
dia supplemented with 10% FBS, 50 U/ml Penicillin-
Streptomycin and 2 mM L-glutamine (Supplementary Ta-
ble S1). H3396 doxycycline-inducible stable cell lines were
generated using pCDNA6-TetR system (Invitrogen) and
pCDNA4- murine IRF1 or vector alone and selected
with Zeocin (200 g/ml). Doxycycline (Dox) was used
at 2 g/ml for indicated time points. Dharmacon ON-
TARGETplus SMARTpools were used for siRNA deple-
tions. All siRNA were used at 10 nM final concentration
for knockdown. Transfection of siRNAwas performedwith
InterFerin (Polyplus). MG132, DRB (5,6-dichloro-1--D-
ribofuranosylbenzimidazole), Dox and CHX (Cyclohex-
imide) were from Sigma Aldrich, GSK3 inhibitors BIO
(6-bromoindirubin-3′ oxime) and methyl-BIO were from
Merck. Details of antibodies used can be found in Supple-
mentary Table S2. The details of primers used can be found
in Supplementary Table S3.
Luciferase reporter assay, Cycloheximide chase assay
Reporter assays; cells were seeded (30 000/well) for 24 h in
24 well plates followed by transfection with reporter con-
struct, IRF1 and internal control CMV-GAL. Lysis was
carried out 48 h post-transfection essentially according to
manufacturer’s instructions (Applied Biosystems). Lumi-
nescence was detected on a Berthold Orion micro-plate lu-
minometer. For analysis of protein degradation, CHXchase
assays were performed as follows; cells were seeded on six-
well plates for 24 h, transfected with 2.5 g/well of IRF1
and 24 h later cells treated with 25 g/ml CHX for the indi-
cated times followed by lysis and immunoblot against IRF1
and -actin loading control.
Immunoprecipitations, ubiquitination assays, GST-pulldown
assays
For immunoprecipitations, cell lysates (0.5 mg) were diluted
in RIPA buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl,
1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM
EDTA) supplemented with protease and phosphatase in-
hibitor cocktail (SIGMA), 1 mM DTT and 100 mM N-
ethylmaleimide (NEM). After pre-clearing for 1 h with Pro-
tein G beads, the lysates were incubated overnight at 4◦C
with the appropriate antibody, washed three times with
RIPA buffer and eluted in loading buffer with boiling. Co-
immunoprecipitations (1 mg lysate) between FLAG-IRF1
and GSK3-HA were carried out as above but with washes
in TNE buffer (10 mM Tris (pH 7.4), 1 mM EDTA and
200 mM NaCl). For GST-F-box co-immunoprecipitations
extracts were made in NP40 lysis buffer (50 mM Tris pH
7.5, 150 mM NaCl, 0.5% NP40 and phosphatase/protease
inhibitors). 0.5 mg of lysate was incubated at 4◦C with
glutathione–sepharose beads (GE Healthcare) for 3 h, fol-
lowed by 3× washes in NP40 buffer and elution in loading
buffer.
For in vitro pulldown assays, GST or GST-IRF1 (1 g)
conjugated GSH beads were diluted in NETN buffer (20
mM Tris–HCl pH 8, 100 mM NaCl, 1 mM EDTA, 0.5%
NP40 and phosphatase and protease inhibitor cocktail). In
vitro translated 35S-labelled proteins (TnT Promega) were
added to GST beads and incubated overnight at 4◦C fol-
lowed by 3× washes with NETN. Boiled eluates were sep-
arated by SDS-PAGE and the gel was fixed in fixing solu-
tion (10% acetic acid 10% methanol) for 30 min before be-
ing treated with amplifier solution (Amersham) for 30 min
with gentle rocking. Gels were dried and exposed to film at
−80◦C.
For ubiquitination assays, 60% confluent 10 cm dishes of
HEK293 were transfected with 6× His-myc-Ub (2.5 g)
or HA-Ub and FLAG IRF1 (2.5 g). Forty hours later,
MG132 (10 M) was added for 5 hr. Duplicate transfected
plates were treated with 0.01% DMSO as vehicle control.
6xHis nickel pulldowns were carried out essentially as de-
scribed (32). Lysate fractionation was performed as de-
scribed (33).
In vitro kinase assays
Recombinant GSK3 (New England Biolabs) was diluted
to 20 ng/l in kinase buffer and incubated with 4 g of
GST-IRF1 orGST. The final concentration of ATPwas 250
M, in 25 l. The reaction was carried out at 37◦C for 1
h, and terminated by the addition of 6 l of 5× Laemmli
buffer (with 100 mM DTT). Samples were separated by
SDS-PAGE and immunoblotted with indicated antibodies.
RNA extraction, reverse transcription, real-time PCR and
ChIP
All RNA extractions, reverse transcription, real-time PCR
reactions and chromatin immunoprecipitations were per-
formed essentially as in (2).
Proliferation assays
Proliferation assays were performed in H3396 stable cell
lines expressing murine IRF1 in pBabeSIN puro under the
control of a tetracycline inducible promoter. These vectors
were used to transduce H3396 together with a retrovirus
encoding the Tet transactivator in a Tet-on configuration
selectable with hygromycin and a Tet-repressor, which con-
sists of a Tet DNA binding domain and a KRAB domain
selectable with neomycin in order to minimize the back-
ground expression. Proliferation assays were carried out by
plating the cells at 300 cells/well on a 96-well plate and
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then treating with Dox at 3 g/ml for the indicated times.
Cells were then trypsinized, re-suspended in PBS/trypan
blue and counted by light microscope using the trypan blue
exclusion method. All cell counts were done in quadrupli-
cate. For proliferation of other lines, cells were transduced
with pBabeSIN puro, IRF1 WT or IRF1 T181A for 48 hr
prior to selection with 1 g/ml puromycin to remove non-
transduced cells. To assess clonal growth, cells were counted
and plated at low dilution (100–500 cells) on 48-well plates
and left to grow for 10 days prior to staining with crystal
violet (0.05% in 50% methanol). For short-term growth as-
says, cells were plated in 24-well plates following puromycin
selection and allowed to grow for 4 days. Cells were counted
in triplicate after trypan blue staining.
Statistics
Unless stated otherwise, all quantitative or semi-
quantitative assays (reporter, QPCR and ChIP) were
performed in three independent experiments with three
technical repeats. *denotes statistical significance with a
P value <0.05 as detected by Student’s t-test **P < 0.01,
***P < 0.005.
RESULTS
IRF1 is phosphorylated by GSK3
In a search for potential IRF1 phosphorylation sites we fo-
cused on a sequence within the IRF1 transactivation do-
main (TAD) that shares similarity to a subset of consen-
sus GSK3 target sites. This sequence is conserved in mam-
malian species and comprises a threonine residue (T181)
with an upstream ‘priming’ residue (S185) (Figure 1A and
Supplementary Figure S1A, B). To determine if IRF1 can
be directly phosphorylated by GSK3 we performed in
vitro kinase assays with recombinant GSK3 and murine
GST-IRF1. The reactionmix was subjected to western blot-
ting using an antibody raised against phospho-threonine-
proline dipeptide. As murine IRF1 contains only a sin-
gle threonine-proline dipeptide sequence, we could there-
fore use this antibody to assess IRF1 T181 phosphoryla-
tion. In addition to a migration shift in the GST-IRF1
protein, we detected phosphorylation of IRF1 after ex-
posure to GSK3 indicating that GSK3 could directly
modify IRF1 (Figure 1B). To support this result, we next
transfected HEK293 cells (which lack detectable endoge-
nous IRF1 protein) with expression vectors for FLAG-
IRF1 (mouse) and GSK3-HA. Lysates were immunopre-
cipitated with the anti-phospho-TP antibody and blotted
with anti-FLAG antibody. In cells transfected with FLAG-
IRF1 only, we were able to detect phosphorylation of IRF1
suggesting that endogenous GSK3 kinases or other kinases
can target this residue. However this signal was increased
upon over-expression of WT GSK3-HA suggesting that
IRF1 T181may be phosphorylated byGSK3 (Figure 1C).
We noted that the sequence surrounding T181 (i.e. 181-
TPALSP-186) is conserved in a subset of phosphopro-
teins (Supplementary Figure S1A) including the transcrip-
tion factor c-Myc (58-TPPLSP-63) and for which there
are commercially available phospho-antibodies. Indeed, we
were able to demonstrate that an antibody raised against
phospho-T58/S62 (pT/S) of c-Myc also detected wild type
GST-IRF1 in a cold kinase assay but not a GST-IRF1
T181A mutant (Figure 1D). To further confirm that this
antibody detects IRF1 phosphorylated at T181, we co-
transfected HEK293 cells with GSK3-HA or empty vec-
tor in combination with FLAG-IRF1 WT, T181A, S185A
or T181A/S185A vectors (Figure 1E). Following immuno-
precipitation, FLAG-IRF1 proteins were blotted with the
pT/S antibody. Again, while an increase in phosphorylation
of wild type IRF1 was detected onGSK3 over-expression,
this antibody failed to detect IRF1 proteins containing
T181A, S185A or both in combination. Similar results were
obtained using a different tag for detection, i.e. YFP-IRF1
(Supplementary Figure S1C). Quantification of the increase
in relative IRF1 T181/S185 phosphorylation upon GSK3
over-expression is shown in Supplementary Figure S1D.
Over-expression of catalytic mutant GSK3 (K85A) did
not promote increased phosphorylation of IRF1, neither
did the R96A ‘priming’ mutant of GSK3 that cannot
phosphorylate residues if a +4 priming site is already phos-
phorylated, suggesting that S185 is likely to function as a
priming residue (Figure 1F). Further the double alanine
mutant of IRF1 migrates more rapidly suggesting modifi-
cation of both residues (Figure 1E). Additionally we con-
firmed GSK3 was the dominant kinase for this site in
HEK293 cells, by using siRNA depletion followed by de-
tection of phosphorylation of immunoprecipitated FLAG-
IRF1 with the pT/S antibody (Figure 1G). To further sup-
port these observations, we demonstrated in MRC5 fibrob-
last lysates the pT/S antibody cross reacted with immuno-
precipitated IRF1 (Figure 1H). Also inH3396 breast cancer
cell lysates the pT/S antibody could immunoprecipitate en-
dogenous human IRF1 induced by IFN treatment (Figure
1I).
Taken together, these data provide evidence that both ex-
ogenous murine and endogenous human IRF1 proteins are
subjected to dual Thr180/181/Ser184/185 phosphorylation by
GSK3.
IRF1 interacts with GSK3
To explore whether IRF1 interacts with GSK3, co-
immunoprecipitations were performed on extracts of
HEK293 cells overexpressing FLAG-IRF1 and GSK3-
HAproteins.We successfully co-precipitated IRF1/GSK3
complexes using either epitope tag (Figure 2A, B). Impor-
tantly we were also able to detect reciprocal co-IP of basal
endogenous IRF1 and GSK3 present in H3396 cells (Fig-
ure 2C). The interaction could also be detected with IFN -
induced endogenous IRF1 in H3396 (Supplementary Fig-
ure S1E). In both basal and IFN -induced conditions,
coIP of these complexes was more robustly detected after
treatment with the proteasome inhibitor MG132, suggest-
ing that the interaction may be associated with degrada-
tion of IRF1. Interaction of these proteins in vitro was con-
firmed byGST-IRF1 pulldownof 35[S}-methionine labelled
GSK3 (Figure 2D). Thus, the observed interactions be-
tweenGSK3 and IRF1 supports our hypothesis that IRF1
is a phosphorylation target of GSK kinases.
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Figure 1. IRF1 is phosphorylated by GSK3. (A) Sequence conservation of the putative GSK3 phospho-target sequence in different species. The phos-
phorylated T180 and the +4 priming site (S184) (T181/S185 inmurine sequence) residues are indicated by black andwhite arrowheads, respectively. Residue
numbers in parentheses. (B) In vitro kinase assay performed using recombinant GSK3 and purified GST-IRF1 protein as substrate. The reaction products
were resolved by SDS PAGE and GST-IRF1 T181 phosphorylation revealed by western blotting using anti-pTP antibody (top panel). Altered migration
of GST-IRF1 after phosphorylation by GSK3 was also visible after western blot detection using anti-IRF1 (middle panel), or by Coomassie brilliant
blue (CBB) staining (bottom panel). The lowest band in the CBB panel is the loading dye front. (C) Lysates from HEK293 cells expressing GSK3-HA
and mouse FLAG-IRF1, immunoprecipitated with the p-TP antibody. Immunoprecipitated IRF1 was detected with anti-FLAG antibody. Inputs (10%)
indicate the expression of transfected FLAG-IRF1 and GSK3-HA proteins, and loading control -actin. (D) In vitro kinase assay performed as in 1B
but visualized by immunoblot with pT/S (pThr58/Ser62 c-Myc) and with GST tag control. The T181A mutant is included to demonstrate specificity of the
antibody. Note: the GST and GST-IRF1 samples were run in parallel on separate SDS-PAGE gels. (E) Lysates of HEK293 cells expressing FLAG-IRF1
WT or mutants together with GSK3-HA or empty vector were immunoprecipitated with anti-FLAG beads. IRF1 T181/S185 dual phosphorylation was
detected by western blotting with pT/S antibody (top panel). Successful IP of IRF1 proteins in the extracts was confirmed by re-probing with anti-FLAG
antibody (second panel). Inputs (10%) are shown in the lower three panels and indicate the levels of IRF1 (anti-FLAG), GSK3 (anti-HA) and loading
control -actin. (F) As for E), but with GSK3 kinase inactive (K85A) and priming mutants (R96A). (G) HEK293 cells treated with siRNAs to deplete
GSK3 (or control) for 24 hr prior to transfection with FLAG-IRF1 for a further 48 hr. Lysates were immunoprecipitated and probed with pT/S anti-
body and FLAG to show IP efficiency. (H) Extracts from MRC5 cells treated for 3 hr with IFN (1000U / mL) or vehicle were immunoprecipitated with
anti-IRF1 and probed with pT/S. Input lysates (10%) are shown below. (I) H3396 lysates (IFN treated as for H) immunoprecipitated with pT/S followed
by probe with IRF1. Input lysates (10%) are shown below against IRF1, GSK3 and -actin.
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Figure 2. IRF1 interacts with GSK3. (A) Extracts from HEK293 cells expressing FLAG-IRF1 and GSK3-HA were immunoprecipitated with anti-
HA. Shown are western blots used to reveal co-precipitated GSK3-HA or FLAG-IRF1 proteins. Expression levels in the inputs (10%) are shown in the
bottom panels. (B) As for (A), but using anti-FLAG immunoprecipitation and including kinase inactive GSK3-HA (K85A) (C) Extracts from H3396
cells pre-treated with MG132 (10 M) or DMSO for 3hr, immunoprecipitated with IgG, anti-IRF1 or anti-GSK3 antibodies to reveal endogenous
complexes. (D) GST pulldown experiment using bacterially expressed, partially purified GST (27kda) or GST-IRF1 (63 KDa) immobilized on glutathione
sepharose beads and incubated with in vitro transcribed/translated 35[S]-methionine-labelled GSK3-HA. Proteins retained on the beads were visualized
by autoradiography. 10% input of radiolabeled product is shown as input. Lower panel shows a parallel CBB stained gel to show loading.
GSK3 is required for IRF1 transcriptional activity
To investigate the effects of phosphorylation on IRF1 ac-
tivity, we measured IRF1-dependent transactivation in re-
porter assays. For overexpression we used Cos7 cells that
lack detectable IRF1, allowing us to discount possible ef-
fects of endogenous IRF1 proteins. Our results showed that
IRF1 reporter activity on the TRAIL/TNFSF10 (TNF
Related Apoptosis Inducing Ligand) promoter fragment
(construct described in (2)) was reduced following treatment
with GSK3 inhibitors LiCl or Inhibitor-BIO but not the in-
active derivative methyl-BIO (Figure 3A, B). This suggested
that GSK3 is required for IRF1-dependent stimulation of
reporter activity. Next, we overexpressedGSK3 in TRAIL
promoter reporter assays, but found no increase in IRF1
activity when GSK3 was over-expressed, however we did
detect a dose-dependent decrease in IRF1 activity when
the K85A (kinase inactive/dominant negative) mutant was
overexpressed (Figure 3C). Given that this mutant inter-
acts with IRF1, but does not phosphorylate it (Figures 2B
and 1F), it is likely to be a dominant negative effect. GSK3
inhibitors do not discriminate between the two GSK3 iso-
forms (/) and can also inhibit other related kinases. To
verify the requirement of GSK3 in IRF1 transcriptional
activity we used siRNA directed against GSK3. Reporter
assays in MRC5 fibroblasts revealed that knockdown of
GSK3 significantly reduced IRF1-mediated activation of
the TRAIL promoter (Figure 3D). These results demon-
strate that GSK3 is required for the full transcriptional
function of IRF1, but over-expressingWTGSK3 does not
potentiate IRF1 activity further. We then wanted to deter-
mine if phosphorylation of residues (Thr181/Ser185) are re-
quired for IRF1 activity. Expression vectors for wild type or
mutant IRF1 proteins were co-transfected with the TRAIL
reporter or 4XISRE (Interferon Stimulated Response El-
ement) reporter constructs in Cos7 cells. All three of the
phosphorylation-deficientmutants displayed reduced activ-
ity in the reporter assays (Figure 3E) despite being expressed
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Figure 3. GSK3 is required for IRF1 transcriptional activity. (A) Reporter assays in Cos7 cells transfected with IRF1 and TRAIL promoter reporter
for 48 h. Cells were treated with NaCl (to control for osmolality) or LiCl for 24 h prior to lysis. Data is expressed as fold luciferase induction by IRF1
over empty vector (pCDNA3.1). All reporter assay data is from three independent experiments assayed in triplicate. Error bars denote SEM and * denotes
statistical significance (P < 0.05) as determined by Students t-test between NaCl and LiCl treatments. Panel below shows IRF1 expression. (B) As for (A)
but treatment with vehicle (DMSO), GSK3 Inhibitor BIO or the inactive analog Methyl-BIO (1, 2.5 and 3.75 M/1 h). (C) Reporter assays using Cos7
cells transfected with TRAIL reporter construct, pcDNA3 (vector), or IRF1 and increasing concentrations of GSK3-HA WT or GSK3-HA K85A
mutant. (D) Reporter assays in MRC5 cells transfected with control or GSK3 siRNAs (10 nM/16 h) followed by transfection with TRAIL promoter
reporter and IRF1 for 24 h. (E) Reporter assay in Cos7 cells transfected with the TRAIL or 4XISRE-Luc reporters in conjunction with IRF1WT, T181A,
S185A and T181A/S185A constructs. Statistical difference is between WT and mutant IRF1. (F) As for (E) but with T181D and S185E mutants in Cos7
and MRC5 cells.
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at similar levels compared to wild type and having nuclear
localization (Supplementary Figure S2A). To confirm these
results we repeated the TRAIL reporter assays in MRC5 fi-
broblast cells and also detected reduced transcriptional ac-
tivity of the phospho-mutants (SupplementaryFigure S2B).
We next generated FLAG-IRF1 phospho-mimetic mutants
T181D and S185E and tested their activity on the TRAIL
reporter in Cos7 and MRC5 cells. Somewhat surprisingly,
these mutants also exhibited reduced activity (Figure 3F).
It should be noted that substitution of aspartate or gluta-
mate can chemically resemble phosphoserine and phospho-
threonine residues and thus mimic some functions, but the
geometry surrounding phosphate group required for proper
recognition by binding proteins may not be fully satisfied.
However, taken together, we can conclude from our data
T181 and S185 residues are required for IRF1 function
in cells and that their substitution with alanine or acidic
residues is not compatible with full IRF1 transactivation
ability.
Expression of IRF1 target genes is dependent on T181 in-
tegrity
Having established that GSK3 and the T181 residues are
required for IRF1 activity in reporter assays, we next as-
sessed the effects of IRF1 substitution mutations on acti-
vation of endogenous gene targets. As the T181A, S185A
and T181A/S185A mutants showed indistinguishable ac-
tivities, we focused on the T181A mutant. Therefore, we
generated tetracycline-inducible H3396 cell lines to condi-
tionally express wild-type IRF1 or T181A mutant with an
empty vector control. As shown in Supplementary Figure
S2C, strong induction of IRF1 proteins was observed after
24 hr Dox treatment. We used these cell lines to assess the
effect of conditional expression IRF1 WT and T181A pro-
teins on endogenous IRF1 target genes that we had previ-
ously validated (5) using RT-QPCR. In contrast to the neg-
ative control, conditional expression of IRF1 WT protein
in H3396 cells resulted in increased expression of TRAIL,
OAS3, PSMA6 and TBC1D32 (TBC1 domain 32, previ-
ously C6orf170) transcripts. However, induction of these
genes by IRF1 T181A was significantly lower (Figure 4A
and Supplementary Figure S2D for an independent batch
of clones), consistent with the results from the reporter as-
says. We next confirmed that the Tet-inducible IRF1 pro-
teins were being recruited to promoters by chromatin im-
munoprecipitation (Figure 4B), and found IRF1 T181A
was detected at similar or higher levels as IRF1 WT. Thus,
despite its efficient expression and robust recruitment to
IRF1 target gene promoters, these results indicate that T181
integrity is essential for full IRF1 transcriptional activity.
IRF1 T181A hampers RNA Pol-II elongation on the
TBC1D32 (C6orf170) gene
Our data indicated that the T181A mutation reduces IRF1
transcriptional activity without compromising its recruit-
ment to target promoters (Figure 4A, B). Therefore to fur-
ther investigate themechanism underlying the unproductive
IRF1 activation due to T181A mutation, we investigated
RNA Pol-II phosphorylation status at an IRF1 target gene.
The transition of RNA polymerase to an effective tran-
scriptional elongating form is well established (34) and in-
volves phosphorylation events, within the CTD (C-terminal
domain) repeat region of Pol-II. We performed ChIP as-
says on chromatin isolated from H3396 cell lines condi-
tionally expressing WT or T181A IRF1, using antibodies
to immunoprecipitate total RNA Pol-II, or elongating Pol-
II (phospho-S2) (Figure 5A, B). We selected the TBC1D32
gene as its promoter has robust resident Pol-II content in
unstimulated cells (5), thus we reasoned this might facilitate
observing the dynamics of Pol-II transition to a transcrip-
tional elongating form (p-Ser2), as promoters with a large
amount of existing Pol-II are usually enriched in the initiat-
ing p-Ser5 form of Pol-II CTD (31, 32). Indeed, a significant
proportion of IRF1 targets that we previously identified by
ChIP-chip [33] fall into this category (Supplementary Fig-
ure S2E, F). Therefore, we considered the TBC1D32 gene
to be a good candidate to investigate how perturbation of
IRF1 phosphorylation might affect the Pol-II transition on
IRF1 target genes. As shown in Figure 5A we observed a
reduction in total Pol-II content at the TBC1D32 promoter
following Dox stimulation of IRF1WT expression, but not
in IRF1 T181A expressing cells. In the case of IRF1 WT,
but not T181A, this was accompanied by an increase in the
amount of pSer2 Pol-II detected within the TBC1D32 gene
body, suggesting transition to elongating Pol-II (Figure 5B).
Thus, these data suggest that IRF1T181 phosphorylation is
required for the transition of promoter-bound RNA Pol-II
to a transcriptional elongating form for effective expression
of an IRF1 target gene.
Phosphorylation of T181/S185 by GSK3 promotes IRF1
degradation
Phosphorylation by GSK3 is known to impact on the
ubiquitination and turnover of some of its substrates, e.g.
c-Myc and c-Jun, which contain similar sequences to the
TPALSP motif in IRF1 (Supplementary Figure S1A) (24).
Further we had noted that over-expression of GSK3 re-
sulted in reduced IRF1 (WT) levels (Figure 1E, lane 7).
Therefore, we tested whether phosphorylation site muta-
tion would alter half-life of IRF1 proteins in MRC5 or
HEK293 cells by CHX chase assays. As shown in Figure
6A,B and Supplementary Figure S3A, B, the T181A, S185A
and T181A/S185A mutants displayed decreased turnover,
suggesting increased stability of these proteins compared
to WT. In contrast, phospho-mimetic mutations T181D
and S185E appeared to induce more rapid turnover than
wild type IRF1. (Figure 6A, B and Supplementary Figure
S3A, B). Similar results were observed in both MRC5 and
HEK293 cells (Supplementary Figure S3B). We next as-
sessed the effect of GSK3 overexpression on the estimated
half-life of IRF1 WT protein (Figure 6C, D). Overexpres-
sion of WT GSK3 in MRC5 cells strongly reduced IRF1
stability in comparison to the vector only control (Figure
6C, D). In contrast, overexpression of the kinase inactive
GSK3 K85A mutant appeared to increase the stability
of IRF1. Similar effects on stability of exogenous IRF1
proteins were observed in HEK293 cells (Supplementary
Figure S3C). Overexpression of WT GSK3 did not alter
the half-life of T181A IRF1 suggesting the destabilization
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Figure 4. T181 is required for full IRF1 transactivation of target genes. (A) IRF1 target gene mRNA expression determined by qRT-PCR. H3396-Tet-Off
cells expressing empty vector (pCDNA4-TO), WT or T181A IRF1, were induced with 2 g/ml Dox for 36 hr. TRAIL, OAS3, PSMA6 and TBC1D32
mRNA is expressed relative to β-actin. Statistical significance was determined between Dox-induced WT and T181A IRF1 expressing cells. (B) ChIP
analysis performed on the cell lines from (A) using either control rabbit IgG antibody or IRF1 M20 (mouse-specific) antibody to prevent any endogenous
IRF1 immunoprecipitation. Data is shown as fold enrichment between cells treated with Dox (36 h 2 g/ml) or vehicle.
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Figure 5. T181 is required for IRF1 to promote RNA Pol-II elongation on
target promoters. (A) H3396 cells expressing Tet-inducible IRF1 WT or
T181A were treated with vehicle or induced with Dox for 36 hr. ChIP was
performed using anti-total RNA-Pol-II, or IgG antibodies (as control).
QPCR was performed to detect enrichment at the TBC1D32 promoter re-
gion containing the IRF1 binding site. (B) ChIP performed as in A, but
using anti-phospho-Ser2 RNA Pol-II antibody and QPCR performed us-
ing primers from within the TBC1D32 gene body to detect the elongating
form of RNA-Pol-II.
of IRF1 by GSK3 requires this residue (Supplementary
Figure S3D). Consistent with these data, depletion of en-
dogenous GSK3 resulted in increased stability of both en-
dogenous (human) and FLAG-tagged (mouse) IRF1 pro-
teins (Figure 6E, F). Pre-treating cells with GSK3 inhibitor
BIO prior to CHX chase also resulted in a stabilization of
IRF1 protein (Supplementary Figure S3E). Taken together,
these data demonstrate convincingly that phosphorylation
of IRF1 at Thr181/Ser185 regulates its stability.
GSK3 promotes IRF1 ubiquitination
IRF1 has previously been shown to be poly-ubiquitinated
in cells (12) which promotes its degradation and short half-
life. We determined the level of ubiquitination on the mu-
tated forms of IRF1 by western analysis of anti-FLAG im-
munoprecipitate from denatured lysates expressing myc-Ub
in the presence ofMG132. This showed that wild-type IRF1
was robustly ubiquitinated while the alanine mutants were
less efficiently ubiquitinated in cells. In contrast, the acidic
mutants had similar or increased ubiquitination compared
to wild-type IRF1 (Figure 7A, B). There was also an in-
crease in IRF1 ubiquitination upon co-transfection with
GSK3 WT, but not GSK3 K85A vectors (Figure 7C).
The requirement of GSK3 for endogenous IRF1 ubiqui-
tination in human cells was determined by siRNA deple-
tion or chemical inhibition. In both cases a large reduction
in ubiquitinated IRF1 was detected following ubiquitin IP
in H3396 cells (Figure 7D). Collectively these data support
the hypothesis that GSK3-mediated phosphorylation of
T181/S185 is required for regulation of IRF1 turnover via
ubiquitination.
IRF1 phosphorylated at Thr181/Ser185 is linked to transcrip-
tion and degradation.
To determine if the T181/S185-phosphorylated pool of
IRF1 is targeted for proteasomal degradation we expressed
GSK3 and IRF1 in HEK293 cells, treated with MG132
and detected phosphorylation as before (Figure 1E). We
found that MG132 lead to a significant increase in the
proportion of IRF1 phosphorylation at Thr181/Ser185 in
both basal and GSK3 overexpression conditions (Figure
8A). This suggests that this phosphorylated form of IRF1
is targeted for proteasome degradation. We next sought
to determine if IRF1 is phosphorylated when bound to
DNA by using a DNA binding domain mutant YLP-A
(Y109A/L110A/P113A) (35). Lysates of HEK293 cells ex-
pressing IRF1 WT or the IRF1 YLP-A mutant were frac-
tionated into cytoplasmic, soluble nuclear and chromatin
pools and probed for IRF1 (Figure 8B, lower panels inputs).
Only a small proportion of WT and T181A IRF1 were de-
tected in the cytoplasmic fraction, in which the DBD mu-
tant YLP-A was more enriched. This was also evident by
indirect immunofluorescence (Supplementary Figure S2A).
The chromatin fractions contain roughly equal amounts of
WT and T181A, but less IRF1 YLP-A suggesting this frac-
tion contains DNA-bound IRF1. After adjusting for IRF1
expression, nuclear and chromatin lysates were immunopre-
cipitated and probed with pT/S antibody. The WT IRF1
was abundantly phosphorylated in the chromatin-enriched
lysates while the YLP-A mutant was poorly phosphory-
lated (Figure 8B). This suggests that DNA binding func-
tionality and the association of IRF1 with chromatin facil-
itate T181/S185 phosphorylation. To determine if T181A
stabilizes the chromatin-enriched pool of IRF1, we per-
formed CHX chases and separated lysates into soluble and
insoluble fractions. While there was little difference in sta-
bility between the WT and T181A mutant in the soluble
pool, the chromatin pool of T181A was more stable than
the WT (Figure 8C). This confirms that T181 contributes
to de-stabilization of chromatin-associated IRF1. Next we
sought to determine if transcriptional elongation regulates
IRF1 phosphorylation using the RNA-Pol-II elongation
inhibitor DRB. Indeed, co-immunoprecipitations between
IRF1 and GSK3 (Figure 8D) and detection of phospho
T181/S185 were both reduced by DRB (Figure 8E). There-
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Figure 6. Phosphorylation of T181/S185 by GSK3 promotes IRF1 degradation. (A) Cycloheximide (CHX) chase to detect turnover of IRF1 proteins.
MRC5 cells expressing IRF1 WT or mutants were treated with CHX to prevent further protein synthesis. Whole cell extracts were prepared at the times
indicated post CHX treatment and subjected to western blotting, using anti-IRF1 antibody. IRF1 expression was quantified using densitometry (ImageJ)
and expressed relative to -actin levels; untreated was set at 100%. Data is from three independent experiments performed in duplicate. Also see Supple-
mentary Figure S3A for t-test significance. (B) Western blot of IRF1 CHX chases related to (A). (C) CHX chase in MRC5 cells expressing IRF1 and
GSK3, calculated as for (A). Error bars = s.e.m., Student’s t-test shows significance between empty vector + IRF1 and GSK3 + IRF1. (D) Western
blot of IRF1 and GSK3 related to (D). (E) MRC5 cells transfected with controL (siCTRL) or GSK3 siRNAs (10 nM) for 24 h followed by transfection
with FLAG-IRF1 for 48 hr. Parallel siRNA transfected samples were treated with IFN (1000 U/ml 3 h) to induce endogenous IRF1 expression and
subjected to CHX chase for indicated times. Lysates were probed with FLAG to detect exogenous IRF1 and IRF1 C20 (human specific) antibody to detect
the endogenous IRF1. Error bars = s.e.m., Student’s t-test shows significance between siCTRL and siGSK3 for mouse and human IRF1. (F) Western
blots from (E) probed for FLAG (exogenous mouse IRF1) and human IRF1 (C20 antibody is non-cross reactive with murine IRF1), GSK3 (knockdown
efficiency) and -actin loading control.
fore phosphorylation at T181/S185 occurs on DNA bound
IRF1, requires RNA-Pol II elongation and promotes pro-
teasomal degradation.
Fbxw7 interacts with IRF1 via Thr181
Many GSK3 substrates are targeted for ubiquitination
by the SCF E3 ubiquitin ligase receptor Fbxw7, and we
noted that phosphorylation of T181/S185 would generate
an Fbxw7 phosphodegron.We tested IRF1 interactionwith
various isoforms of Fbxw7 (// ). HEK293 lysates ex-
pressing GST-Fbxw7 isoforms were subjected to GST pull-
downs and demonstrated that IRF1 preferentially inter-
acts with the nuclear form; Fbxw7 (Supplementary Fig-
ure S4A, B). The interaction was confirmed by reciprocal
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Figure 7. GSK3 promotes IRF1 ubiquitination. (A) Ubiquitination of IRF1; HEK293 cells expressing FLAG-IRF1, and MYC-Ub were treated with
MG132 (10 M) for 6 h prior to IP for FLAG-IRF1 and probe with myc (Ub-IRF1). Input lysates were probed with anti-FLAG, anti-myc and anti-
vinculin. (B) Quantification of relative levels of ubiquitination of IRF1 proteins. Data is expressed as the relative levels of the IRF1-Ub species versus
the IRF1 from inputs (to account for differences in expression). Data is from three experiments. Error bars denote SEM. Significant differences were
determined by Student’s t-test comparing WT to each mutant. (C) HEK293 cells expressing HA-Ub, FLAG-IRF1 WT, GSK3-HA WT and GSK3
-HA K85A were lysed 48 hr post transfection in SDS denaturing buffer, boiled and diluted 10-fold in PBS and immunoprecipitated with FLAG. The
resulting high molecular weight Ub modified IRF1 was detected by HA western blot. Input panel shows expression of transfected proteins. (D) Ubiquitin
immunoprecipitation of endogenous IRF1 in MRC5 lysates from cells siRNA depleted of IRF1 or GSK3, or pre-treated with GSK3 Inhibitor BIO, or
its inactive analog met-BIO (10 M for 1 h). MG132 (10 M for 5 h) was added prior to lysis to prevent degradation of ubiquitinated IRF1. Ub-IRF1
smears were detected by blot against human IRF1 using the C-20 antibody. Knockdown efficiencies for IRF1 and GSK3 are shown in the input panel.
Control IgG immunoprecipitation is shown on the adjacent panel.
co-IP in HEK293 cells (Figure 9A, B). IRF1 did not in-
teract with a WD40 domain deletion of Fbxw7 (Figure
9B), suggesting that the interaction with IRF1 is phospho-
rylation dependent as observed for other substrates. The
interaction was substantially increased when IRF1 phos-
phorylation was enhanced byGSK3 over-expression (Fig-
ure 9C). Further, IRF1 T181D increased, while T181A de-
creased interaction with Fbxw7 (Figure 9D). These data
demonstrate a phosphorylation-dependent interaction be-
tween IRF1 and Fbxw7.
Fbxw7 regulates IRF1 ubiquitination, half-life and tran-
scriptional activity
We next determined what effect Fbxw7 has on the stabil-
ity of IRF1. Co-transfection of Fbxw7with IRF1 resulted
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Figure 8. IRF1 phosphorylated at T181/S185 is linked to transcription and degradation. (A) HEK293 cells expressing FLAG-IRF1 with GSK3-HA
or empty vector were treated with 10 MMG132 or DMSO for 6 hr prior to lysis. Following immunoprecipitation with anti-FLAG beads, western blots
were performed using the anti-pT/S antibody and re-probed with anti-FLAG to determine total IRF1 protein, and a representative blot is shown. The
ratio phospho-IRF1 to total IRF1 was quantified by densitometry, and data from three independent experiments are shown. Error bars denote SEM and
* indicates P>0.05 by Students t-test. (B) Extracts from HEK293 cells expressing WT, T181A or YLP-A IRF1 proteins were separated into cytoplasmic,
nuclear and chromatin fractions. Nuclear and chromatin lysates were immunoprecipitated with anti-FLAG after adjustment for IRF1 expression levels
and blotted with the anti-pT/S antibody. Lower panels show expression of IRF1 mutants in fractions and GAPDH as a cytoplasmic marker and Histone
H3 as a chromatin marker. (C) HEK293 cells expressingWT or T181A IRF1 were CHX chased for indicated times, lysates were prepared in 200 mMNaCl
buffer (nuclear soluble) and insoluble pellets (chromatin) were further digested by incubation in 500 mM NaCl buffer supplemented with DNase I. The
two separated fractions were probed for FLAG-IRF1. Panel below shows western blots related to panels above, -actin was used as a soluble and Lamin
B1 as an insoluble loading control. Statistical difference is between WT and T181A IRF1. (D) HEK293 cells expressing FLAG-IRF1 and GSK3-HA for
48 hr were treated with DRB (1 M/1 h) prior to lysis and immunoprecipitation with FLAG. Inputs are shown below. (E) H3396 cells were pre-treated
with DRB (1 M/1 h) to inhibit transcription prior to immunoprecipitation with pT/S and blot with IRF1 antibody.
in decreased stability of IRF1 in MRC5 CHX chase experi-
ments. No effect on IRF1 estimated half-life was detected
upon co-transfection with WD40 Fbxw7 (which does
not interact with IRF1) (Supplementary Figure S5A, B).
Conversely, Fbxw7 siRNA increased the stability of IRF1
(for both exogenous FLAG IRF1 and endogenous human
IRF1) in MRC5 (Figure 10A and Supplementary Figure
S5C).We also performedHis-UbWT andUbK48O (K48 only)
pulldowns of IRF1 with GSK3 or Fbxw7 overexpres-
sion and detected an increase in IRF1 ubiquitination when
either of these proteins were overexpressed (Figure 10B).
This suggests GSK3/Fbxw7 promotes K48-linked ubiq-
uitination of IRF1. To determine if this ubiquitination was
important for IRF1 function we measured IRF1 activity
in Fbxw7-depleted cells and noted a significant reduction
in TRAIL reporter activity (Figure 10C). Next we wanted
to further confirm the importance of Fbxw7 in IRF1
function so sought to map the lysine residues targeted by
the SCFFbxw7 ligase. As GSK3-Fbxw7 targets DNA-
bound IRF1we reasoned that lysineswithin theDBDmight
be masked, and thus focussed on the remaining five C-
terminal lysine residues. Each of the K→R mutants were
expressed with and without Fbxw7 and subjected to His-
Ub pulldowns as before. Increased ubiquitination following
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Figure 9. Fbxw7 interacts with phosphorylated IRF1 via T181. (A) Co-immunoprecipitation of HA-Fbxw7 in extracts of HEK293 cells, and western
blots using anti-HA antibody to detect associated FLAG-IRF1. Cells were treated with MG132 for 6 h prior to lysis. Blots were re-probed with anti-HA
to determine IP efficiency n.s. = non-specific band is indicated. (B) Co-IP experiment as in (A) but with anti-FLAG antibody to IP and western blot with
anti-HA to detect complex formation with HA-Fbxw7 or a mutant lacking the WD40 domain (HA-Fbxw7 WD40). (C) HA-Fbxw7, GSK3-HA
and FLAG-IRF1 were co-expressed in HEK293 for 48 h, 6 h prior to lysis cells were treated with 10 MMG132. Lysates were immunoprecipitated with
anti-FLAG and probed with anti-HA to detect Fbxw7 interaction. The blots were also probed with the anti-pT/S antibody and FLAG to determine
relative levels of IRF1 phosphorylation. (D) Immunoprecipitations as for (B) but with the inclusion of IRF1 T181A, S185A, T181A/S185A and T181D
mutants.
Fbxw7 overexpression was observed with theWT, K276R
and K300R variants, while K233R, K240R and K255R
were less efficiently hyper ubiquitinated, suggesting these
residues, and in particular K240 may serve as targets of
SCFFbxw7 (Figure 10D and Supplementary Figure S5D).
These mutants also show reduced overall ubiquitination
with the UbWT and UbK48O mutant but not the UbK63O or
UbK6O variants suggesting they are acceptors of K48-Ub
linkages, while K6 and K63-Ub chains are formed on other
lysine residues (Supplementary Figure S5E). The Fbxw7
insensitive mutants are also more stable (Figure 10E, F)
and less transcriptionally active on both the TRAIL and
4XISRE reporters (Figure 10G and Supplementary Fig-
ure S5F). Collectively, these data demonstrate that Fbxw7
ubiquitinates IRF1 at several residues with the C-terminal
region which regulates its stability and transcriptional ac-
tivity.
IRF1 T181 is required for anti-proliferative activity in cancer
cells
The anti-proliferative action of IRF1 is well studied and
contributes to tumour suppressor activity (3). To investigate
the contribution of T181 phosphorylation to IRF1 activity
we measured proliferation of H3396 cells using the KRAB-
Tet system. As even low IRF1 expression affects cancer cell
growth we used this system as it promotes a much more ro-
bust silencing of IRF1 expression prior to the addition of
Dox.
We measured proliferation rates in vector, WT and
T181A expressing H3396 stable cell lines. Induction of WT
IRF1 resulted in a marked decrease in growth of H3396.
In contrast, the T181A mutant showed no inhibition of
growth similar to empty vector control (Figure 11A). We
next assayed clonal growth in a number of puromycin-
selected cell lines constitutively expressing vector, WT or
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Figure 10. Fbxw7 regulates IRF1 ubiquitination, half-life and transcriptional activity. (A) MRC5 cells transfected with control or Fbxw7 siRNAs (10
nM) for 24 hr followed by transfection with FLAG-IRF1 for 48 hr. Parallel siRNA transfected samples were treated with IFN (1000U/ml 3 hr) to induce
endogenous IRF1 expression and subjected to CHX chase for indicated times. Lysates were probed with FLAG to detect exogenous IRF1 and IRF1 C20
antibody to detect the endogenous IRF1. Errors bars = s.e.m., Student’s t-test shows significance between siCTRL and siFbxw7 for mouse and human
IRF1. (B) HEK293 cells expressing FLAG-IRF1, GSK3-HA and 6xHis-Ub (WT or K48 only) for 48 h prior to a 6 h 10 MMG132 treatment. Lysates
were prepared in 8M urea buffer and incubated with nickel agarose to enrich His-Ub modified proteins. Pulldowns were probed with anti-FLAG to detect
Ub-IRF1. 10% inputs show expression of transfected proteins. (C) Reporter assay inMRC5 cells transfected with the TRAIL promoter-Luciferase reporter.
Cells were transfected with the indicated siRNAs overnight prior to transfection with reporter and IRF1 expression vector for 24 h prior to lysis. Error bar
denotes SEM and * statistical significanceP(>0.05) as determined by Students t-test between control and Fbxw7 siRNA treated cells. (D) Quantification of
relative ubiquitination of indicated IRF1 K→Rmutants. HEK293 cells expressing FLAG-IRF1, HA-Fbxw7 and 6xHis-UbWT for 48 h prior to a 6 h 10
M MG132 treatment. Lysates were prepared in 8M urea buffer and incubated with nickel agarose to enrich His-Ub modified proteins. Pulldowns were
probed with anti-FLAG to detect Ub-IRF1. Data is shown as % increase in ubiquitination between empty vector and HA-Fbxw7 expressing pulldowns.
See Supplementary Figure S5D for western blot panels. (E) CHX chase of MRC5 transfected with indicated IRF1 mutants as for A). (F) Western blot
related to (E). (G) Reporter assay inMRC5 cells transfected with the TRAIL promoter-Luciferase reporter. Cells were transfected with the indicated IRF1
expression vector for 48 hr prior to lysis. Error bar denotes SEM and * statistical significance P(>0.05) as determined by Student’s t-test.
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Figure 11. T181 is required for IRF1 anti-proliferative activity in cancer cells. (A) H3396 KRAB-Tet stable inducible cell lines expressing IRF1, T181A or
vector only were plated at equal concentrations and treated with Dox or vehicle. Proliferation was monitored for 6 days using cell counting. Graph shows
the average of three independent experiments performed in quadruplicate± standard deviation. (B) Indicated cell lines were transduced with pBABE-puro,
IRF1 WT or IRF1 T181A, selected with puromycin for 48 h to remove uninfected cells and plated at 500 cells/well on 48-well plates in quadruplicate.
Clones were left to grow for 10 days before crystal violet staining. Representative wells are shown. (C) Cell lines transduced with retroviruses as for (B)
and allowed to grow in puromycin supplemented media for 7 days prior to trypan blue counting. Viable cells were counted from triplicate wells and the %
change in viable cell number was calculated relative to empty vector. *** indicates a P value less than 0.001 between groups. Abbreviations, Bl (Bladder),
Lu (Lung), Br (Breast), Pa (Pancreas), Co (Colorectal), Me (Melanoma), Ov (Ovarian), Ki (Kidney). (D) Cells treated as for (C) but plated on coverslips
and assayed by indirect immunofluorescence for Ki67 expression after 7 days. Cells stained with strong nucleolar Ki67 were counted as proliferative.
Proliferation was measured relative to empty vector transduced cells. Negative values indicate reduction in Ki67/proliferative cells.
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T181A IRF1. Compared to empty vector,WT IRF1 expres-
sion reduced clonal growth ability in the majority of lines,
while the T181A mutant had less impact. (Figure 11B).
We expanded the analysis with more cell lines and assayed
short-term growth effects in puromycin selected cells. As
with clonal growth, the number of viable cells was signifi-
cantly reduced in WT versus T181A expressing lines. (Fig-
ure 11C). A number of cell lines have been identified to
harbour deleterious mutations in Fbxw7, these mutations
cluster in hotspots within the WD40 repeats and result in
a loss of phospho-specific binding [28], additionally some
cell lines lack Fbxw7 expression due to homozygous dele-
tions. We tested 7 such lines for their ability to respond to
IRF1 overexpression (Figure 11C and Supplementary Fig-
ure S6A). Remarkably these lines were resistant to the ef-
fects of IRF1 expression, suggesting loss of Fbxw7 func-
tion may render cancers resistant to some of the tumour
suppressor activities of IRF1. We noted that enforced ex-
pression of IRF1 did not increase the proportion of non-
viable/dead cells suggesting the effect on cell numbers is
caused by reduced proliferation rather than increased death.
We measured proliferation in vector, WT and T181A cells
by scoring the proliferative marker Ki67 and noted a re-
duction in proliferation in WT IRF1 expressing cells but
less so in T181A expressing cells, as before the prolifera-
tion of Fbxw7 defective lines were only marginally affected
by IRF1 expression (Figure 11D). Collectively, this suggests
the T181 residue is essential for the anti-proliferative pheno-
type of IRF1 expression and that Fbxw7 status is important
for this activity.
DISCUSSION
Here we report a novel mechanism for IRF1 transcriptional
control centring on phosphorylation-dependent degrada-
tion. This tightly controlled clearance is important for IRF1
dependent RNA-Pol-II elongation, mRNA generation and
anti-proliferative activity.
Several reports have identified Ub E3 ligases that tar-
get IRF1. The CHIP E3 ligase was shown to ubiquitinate
IRF1 using both K48 and K63 linkages (13). Subsequently,
MDM2 was found to mono-ubiquitinate IRF1 but did not
regulate its turnover (14). Finally, cIAP2 was reported to
specifically modify IRF1 via K63-linked Ub during IL-1
signalling, but also did not impact on turnover (16). Each of
these E3 ligases conjugates Ub to different lysine residues,
which mostly reside in the DNA binding domain. Ubiquiti-
nation site profiling also identified residues within the DBD
as the major modified sites (14,16,36). In the case of CHIP,
IRF1 is ubiquitinated in the DBD when in its non-DNA
bound form. DNA binding thus shields these residues from
CHIP-dependent degradation (13).
We propose the following model for how ubiquitination
and degradation are required for IRF1 transcriptional ac-
tivity (Figure 12). De novo IRF1 protein is induced follow-
ing stimulation with agents such as IFN . The steady state
levels of non-DNA bound IRF1 are maintained by E3 lig-
ases (such as CHIP), which target this pool for degradation.
IFN signalling induces a widespread recruitment of IRF1
to target genes. DNA-bound IRF1 is then protected from
degradation as lysines in the DBD are shielded fromUb E3
ligases. The difference in half-life of nucleoplasmic versus
DNA engaged IRF1 most likely reflects the ‘time’ required
for other signalling/remodelling/recruiting events to occur
prior to successful transcriptional elongation. We propose
that following firing of RNA polymerase II into the elon-
gation phase, GSK3 dependent phosphorylation marks
IRF1 as ‘spent’, which then targets SCFFbxw7 to ubiquiti-
nate C-terminal lysine residues and promote proteasome
dependent degradation. Essentially, this represents a tran-
scriptional time clock (37,38). This coordinated response,
allows IRF1 to successfully engage the transcriptional ap-
paratus before it is marked for degradation. Importantly,
further rounds of transcription would only occur if there is
a continued presence of a stimulus (e.g. IFN ) to produce
additional IRF1 protein. This is similar to the observations
of cyclic turnover of ER at its target promoters in response
to estrogen signalling (39). This modulation of IRF1 ac-
tivity likely acts as a restraint to prevent hyper-activation
of target genes which includes regulators of processes that
need to be tightly controlled-such as inflammation, apopto-
sis and cell cycle. Interestingly, this regulation must be bal-
anced, as the transcriptional regulation by IRF1 is dually
sensitive to perturbation, hypo- or hyper-stimulation (such
as the acidic mimic mutants) leads to disruption of IRF1
activity. This suggests that any de-coupling of IRF1 activ-
ity from ‘inducing stimuli’ will lead to a restriction of target
gene activation.
We have demonstrated with the T181A mutant that per-
turbation of this clearance has significant effects on IRF1
function. Failure to efficiently remove IRF1 from promot-
ers appears to prevent further elongation of RNA-Pol II,
reduces target gene mRNA transcript abundance and ab-
lates IRF1’s anti-proliferative activity in a number of cell
types. The alanine mutants do however retain some tran-
scriptional activity in reporter assays and mRNA induc-
tion. While these mutants are more stable than WT IRF1
they are still degraded - perhaps suggesting other pathways
can promote IRF1 clearance from promoters.
The dysfunctional nature of T181Amay also offer insight
into mechanisms that disrupt IRF1 activity. Inability to
clear DNA bound IRF1 may also expose it to modification
by SUMO (Small Ubiquitin-related Modifier). SUMOyla-
tion of C-terminal lysines has been shown to stabilize IRF1
by competing for ubiquitination. Hyper-SUMOylation of
IRF1 has been detected in ovarian cancers, and is known to
disrupt IRF1 transcriptional activity (40).
Loss of function in the GSK3-Fbxw7 axis occurs in
several cancer types (31). This is recognized as cancer pro-
moting due to the increased abundance of several oncogenic
factors such as c-Myc, c-Jun, cyclin E and NOTCH. Indeed
the majority of Fbxw7 substrates are oncogenic, which
makes IRF1 (a putative tumour suppressor) an unusual
substrate for this pathway. Our data suggests that rather
than targeting IRF1 to reduce overall abundance – which
would impede its tumour suppressive function, GSK3-
Fbxw7 aid in the timely clearance ofDNA-bound IRF1 to
support additional rounds of transcription and thus down-
stream phenotypes such as reduced proliferation. Indeed
cancer cell lines with detective Fbxw7 are largely resis-
tant to the anti-proliferative activities of IRF1 suggesting
that Fbxw7 is an important co-activator of IRF1 function.
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Figure 12. Schematic depicting a proposed model of the regulation of IRF1 activity by GSK3 kinases. 1) External stimuli (such as IFN signalling
activate STAT1 leading to increase expression of cellular IRF1 protein. 2) Steady state levels of IRF1 protein are maintained by the Ub proteasome system.
Non-DNA bound IRF1 is ubiquitinated at lysine residues exposed within the DBD. 3) Nuclear IRF1 binds recognition sequences in target promoters.
In many cases such as TBC1D32 gene, these IRF1-bound promoters are marked by high levels of pSer5 (initiating) modified RNA-Pol-II and are thus
poised for transcription. Engagement with DNA shields the lysines within the DBD from recognition by E3 ligases and subsequent degradation by the
proteasome. This allows time for further events that are necessary for transcription to occur. 4) Transcription is initiated, RNA-Pol-II is marked with pSer2
(elongating). 5) Successful initiation triggers phosphorylation of IRF1 at T181/S185 by GSK3. It is not known how this phosphorylation senses RNA-
Poll firing, perhaps a reorganization of proteins at the promoter unmasks epitopes in IRF1 allowing binding and phosphorylation. 6) Phosphorylation of
IRF1 generates a phospho-degron recognized by SCFFbxw7, which promotes K48 linked ubiquitination of IRF1. 7) IRF1 is degraded by the proteasome.
It is not known if the degradation occurs while IRF1 is bound to DNA, or if a release of IRF1 occurs beforehand. 8) The previously occupied element is
now free for additional molecules of IRF1 (or other proteins) to re-bind and begin a new cycle of transcription. Local concentrations of IRF1 protein –
determined by the balance between de novo generation of IRF1 and degradation will help dictate whether this additional cycle occurs.
Collectively, our data supports an essential contribution of
GSK3-Fbxw7 to the tightly regulated turnover of IRF1
protein during the transcriptional cycle and, thus its anti-
cancer activities (35,41).
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